Právní předpis byl sestaven k datu 12.04.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
Ministerstvo xxxxxxxxxxxx xxxx sděluje, že xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx dopingu xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Českou republikou.
Nové xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x souladu x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Přílohu X xxx xxx 2023, xxxxxxx xx 1. ledna 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Českou xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 a xxxx xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. JUDr. Xxxxxx, Xx.X., XX.X., x. r.
vrchní xxxxxxx xxxxx právní a xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx a metod xxxxxxx je xxxxxxx Xxxxxxxxxxx xxxxxxxx v xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx xx každoročně xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx agenturou (XXXX). Xxxxxx xx xxxxxx od 1. xxxxx 2024.
Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx mezi anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění v xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx látek x xxxxx.
Xxxxxxxx Při xxxxxxx
Xxxxx XXXX pro xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, je xxxxxx Xxx soutěži v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 hodin) x den předcházející Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx xxxxx
Xx xxxxxxx, xx daná xxxxx nebo xxxxxx xx xxxxxxxx Xxx xxxxxxx i Mimo xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Specifickými xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx v Seznamu xxxxxxxxxx látek x xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx neměly xxx xxxxxx způsobem xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx xxxx metody. Xxx xxxxx o xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx látky
Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx xxxxxxxx x xxxxxx jejich častého xxxxxxxxxx xx společnosti xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).
S0 NESCHVÁLENÉ XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx zakázané látky x xxxx třídě xxxx Xxxxxxxxxx látky.
Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx se nevztahuje xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx a xxxxx xxxx x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx orgánem xxx xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x předklinickém xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.
Xxxx xxxxx zahrnuje xxxxx xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 ANABOLICKÉ XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx látky.
Anabolické xxxxx xxxx zakázány.
S1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) |
|
|
• |
1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion) |
• |
metandriol |
|
|
• |
7ɑ-hydroxy-DHEA |
• |
metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on) |
• |
prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol) |
• |
quinbolon |
|
|
• |
dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on) |
• |
testosteron |
|
|
• |
epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, enobosarm (xxxxxxx), LGD-4033 (ligandrol), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.
X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X MIMETIKA
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.
Následující xxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky jsou xxxxxxxx.
X2.1. ERYTROPOETINY (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx jiné xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. XXX-Xx, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Aktivační xxxxxxxxxx hypoxii vyvolávajícího xxxxxxx (XXX), např. xxxxxx; daprodustat (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.
X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Agonisté xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX XXXXXXX A XXXXXX UVOLŇUJÍCÍ FAKTORY
S2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x xxxx, xxxx xxxx včetně:
• xxxxxxxx xxxxxxxxxxxx (XX),
• luteinizační xxxxxx (LH),
• xxxxxx xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (např. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin),
• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx uvolňující faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx hormon (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:
• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, např. XXX-9604 x hGH 176–191.
X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, mimo xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx a tesamorelin,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (MK-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x tabimorelin],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].
X2.3. XXXXXXX FAKTORY X MODULÁTORY XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• hepatocytový xxxxxxx xxxxxx (HGF)
• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx růstové faktory (XXX)
• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)
• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX)
x xxxxx růstové xxxxxxx xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 BETA-2 XXXXXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO SOUTĚŽ)
Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x xxxxxxxxxxxx beta-2 xxxxxxxx včetně všech xxxxxxxxx xxxxxxx jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx dávce;
• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx vilanterol: xxxxxxxxx 25 mikrogramů xx 24 hodin.
POZNÁMKA
Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxx vyšším xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx látky x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx byl důsledkem xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx xxxx xxxxxxx maximální dávky.
S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxxx látky ve xxxxxxx S4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 jsou Nespecifické xxxxx.
Xxxxxxxxxxx hormonové a xxxxxxxxxxx modulátory jsou xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX LÁTKY [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx xxxx včetně:
|
• |
protilátky xxxxxxxxxxxxxx aktivin X |
• |
xxxxxxxxxx xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx xxxxxxxxx xxxx xxxxxx expresi xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx aktivinu (xxxx. XXX-031) |
- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu) |
|||
|
• |
protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (např. bimagrumab) |
- xxxxxxxxxx neutralizující myostatin xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (XX1516, GW501516) x xxxxxxxx Xxx-xxxɑ , xxxx. XX9009, XX9011
X4.4.2 insuliny a xxxxxxxx insulinů
S4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 DIURETIKA A XXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny zakázané xxxxx v této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Xxxxxxxxx, xxxx např.:
acetazolamid; amilorid; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;
• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, hydroxyetyl škrob, xxxxxxxx;
• Xxxxxxxxxxx;
• Probenecid;
a xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; xxxxxxxx; x lokální xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx látky xx stanoveným xxxxxxxx xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (kromě lokálního xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu x xxxxxxxx anestezii), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec nemá xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx tuto xxxxx xxxxx k xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx s výjimkou xxxxx v X2.2, xxx xxxx Specifické xxxxxx.
X1. MANIPULACE S XXXX X KREVNÍMI XXXXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx produktů z xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.
X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.
Mimo xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; efaproxiral (RSR13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví xxxx x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X2.1. Podvádění xxxx Xxxxx o podvod xx účelem porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, např. xxxxxxxx xxxxxxx ke Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx více než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, které xxxxx změnit xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx jakýmkoliv xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx x xxxxxxxx látek xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: kokain x metylendioxymetamfetamin (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a l-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden v xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.
X6.X: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (parahydroxyamfetamin) |
• |
fenmetrazin |
||
|
• |
benzfetamin |
• |
isomethepten |
• |
fenprometamin |
||
|
• |
katin1) |
• |
levmetamfetamin |
• |
propylhexedrin |
||
|
• |
katinon x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (dimetylamfetamin) |
• |
metylendioxymetamfetamin |
• |
selegilin |
||
|
• |
efedrin3) |
• |
metylefedrin3) |
• |
sibutramin |
||
|
• |
epinefrin (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• klonidin;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia xxxxxxxx xx Xxxxxxxxxxxxxx programu 20245).
X7 NARKOTIKA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (heroin)
Následující xxxxxxxxx, včetně jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. d- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx a xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (heroin) |
• |
metadon |
• |
oxykodon |
• |
tramadol |
|||
|
• |
oxymorfon |
S8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny zakázané xxxxx x této xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx látky x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, např.
• x xxxxxx (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• přírodní x xxxxxxxxxx tetrahydrokanabionoly (XXX)
• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx THC
VÝJIMKY
• kanabidiol
S9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx v xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx podávány jakoukoliv xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx cestou.
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx a xxxxxxxxxxxx) nejsou zakázány, xxxxx se xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.
X1 BETA-BLOKÁTORY
ZAKÁZANÉ X URČITÝCH XXXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.
Beta-blokátory xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx na xxxxxx, xxxxxxxxxxx skoky / X-xxxxx x xxxxxxxxx X-xxxxx / xxx xxx
• xxxxxxxxxxxx xxxxx (FIA)
• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx a xxxxxxx na xxxx
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (XXX)
• xxxx (XXX)
• xxxxxxxx (XXX)
• xxxxxxx (XXXX, XXX)*
* xxxxxxxx xxxx Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Znění xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: je xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 150 mikrogramů x 1 xx.
3) xxxxxxx x metylefedrin: zakázány xxx xxxxxxxxxxx v xxxx xxxxx než 10 xxxxxxxxxx x 1 xx.
4) epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, oční, xxxx xxxxxxxx podávání x xxxxxxxxx xxxxxxxxxx.
5) bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu